Loading clinical trials...

Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults | Clinical Trials | Clareo Health

TERMINATEDPHASE3

Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults

A Comparison of Symbicort Single Inhaler Therapy (Symbicort Turbuhaler 160/4.5 Micrograms, 1 Inhalation b.i.d. Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adults - a 26-week, Randomised, Open-label, Parallel-group, Multicentre Study. Study SPAIN

NCT00385593•AstraZeneca

View on ClinicalTrials.gov

Summary

This study is intended to extend the knowledge of Symbicort Single Inhaler Therapy into a more general setting in order to assess the real-life impact of introducing this new treatment concept. The study will compare the Symbicort Single Inhaler Therapy concept with a conventional stepwise treatment regimen according to the investigator's judgement in patients who present with symptoms on inhaled glucocorticosteroids (GCS) treatment or who require and are already on treatment with a combination of inhaled and long-acting B2 agonists (LABA).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Minimum of 3 months history of asthma, diagnosed according to the American Thoracic Society (ATS) definition (9).
•Prescribed inhaled GCS at a dose of 400μg/day of budesonide (or equivalents)and within the approved label for the relevant drug during the last 3 months prior to Visit 1.
•Either daily maintenance treatment with both inhaled GCS and LABA or daily treatment with inhaled GCS alone (i.e. without LABA)
•A history of suboptimal asthma control the month prior to enrolment as judged by the investigator
•Use of ≥3 inhalations of as needed medication for symptom relief during the last 7 days before enrolment

Exclusion Criteria

•Previous treatment with Symbicort Single Inhaler;
•Use of any b-blocking agent, including eye-drops and oral GCS as maintenance treatment.
•Known or suspected hypersensitivity to study therapy or excipients.
•A history of smoking ≥ 10 pack years.
•Asthma exacerbation requiring change in asthma treatment during the last 14 days prior to or at Visit 1.

Locations (52)

Research Site

A Coruña, Spain

Research Site

Alagón, Spain

Research Site

Alicante, Spain

Research Site

Almoradí, Spain

Research Site

Barcelona, Spain

Research Site

Burgos, Spain

Research Site

Cadiz, Spain

Research Site

Caravaca, Spain

Research Site

Cartagena, Spain

Research Site

Coslada, Spain

Key Dates

Start Date

September 1, 2006

Completion Date

October 1, 2008

Last Updated

December 16, 2010

Enrollment

654

ACTUAL participants

Conditions

Asthma, Bronchial

Interventions

Symbicort (budesonide/formoterol) Turbuhaler

DRUG

Conventional treatment

DRUG

A Non-interventional, Prospective Study With Benralizumab

NCT06422078

Asthma, Bronchial

View study

COMPLETEDPHASE4

Study of Montelukast and Its Effect on Lower Leg Growth in Children With Asthma (MK-0476-254)

NCT00092092

Asthma, Bronchial

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 16, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions